Get startedLog in
    Picture of Protide Pharmaceuticals logo

    PPMD — Protide Pharmaceuticals Income Statement

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro Cap
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual income statement for Protide Pharmaceuticals, fiscal year end - August 31st, USD millions except per share, conversion factor applied.

    1999
    August 31st
    2000
    August 31st
    2001
    August 31st
    2002
    August 31st
    2003
    August 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:10KSB10KSB10KSB10KSB10KSB
    Standards:
    USG
    USG
    USG
    USG
    USG
    Status:FinalFinalFinalFinalFinal
    Revenue
    Total Revenue0.1980.2010.2040.4090.504
    Cost of Revenue
    Gross Profit0.1150.1080.1090.2490.363
    Selling / General / Administrative Expenses
    Research And Development
    Total Operating Expenses0.5960.5370.6060.6190.601
    Operating Profit-0.398-0.336-0.402-0.21-0.097
    Total Net Non Operating Interest Income / Expense
    Other Net Non Operating Costs
    Net Income Before Taxes-0.364-0.307-0.363-0.202-0.097
    Provision for Income Taxes
    Net Income After Taxes-0.364-0.307-0.363-0.202-0.097
    Net Income Before Extraordinary Items
    Extraordinary Items
    Net Income-0.364-0.307-0.363-0.202-0.097
    Income Available to Common Shareholders Excluding Extraordinary Items
    Income Available to Common Shareholders Including Extraordinary Items
    Dilution Adjustment
    Diluted Net Income-0.364-0.307-0.363-0.202-0.097
    Diluted Weighted Average Shares
    Basic EPS Including Extraordinary Items
    Diluted EPS Including Extraordinary Items
    Diluted EPS Excluding Extraordinary Items
    Normalised Income Before Taxes
    Normalised Income After Taxes
    Normalised Income Available to Common Shareholders
    Diluted Normalised EPS-0.129-0.094-0.097-0.053-0.024
    Dividends per Share